Protagonist Therapeutics

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Positive results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235) in moderate-to-severe psoriasis, paving a path forward for initiation of a Phase 3 pivotal study Highly statistically significant results from the randomized withdrawal portion of the REVIVE study of rusfertide in polycythemia vera, achieving its primary endpoint of proportion of responders on rusfertide versus placebo (p=0.0003) NEWARK, CA / ACCESSWIRE / March 15, 2023 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. "The positive FRONTIER 1 JNJ-2113 (PN-235) data recently reported represents a scientific breakthrough with the potential to transform the treatment landscape for moderate-to-severe plaque psoriasis with oral targeted therapy.

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Rusfertide met the study's primary endpoint, with a statistically significant higher number of responders on rusfertide versus placebo (p=0.0003) Rusfertide continues to be generally well tolerated with no new safety signals NEWARK, CA / ACCESSWIRE / March 15, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company"), today announced positive topline results from the blinded, placebo-controlled, randomized withdrawal portion of REVIVE, a study evaluating rusfertide, a subcutaneous injectable hepcidin mimetic, in patients with polycythemia vera (PV). Subjects receiving rusfertide achieved highly statistically significant improvements versus placebo in the primary endpoint.

Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera

With back-to-back clinical data readouts of Protagonist Therapeutics' lead product candidates this month, the first one led to a 50% run. This agent being picked for Phase 3 development on the strength of these statistically significant but mysterious results is another catalyst.

Protagonist Therapeutics: More Good News Likely To Come

Protagonist (PTGX) gains as the phase II study, conducted by Janssen, achieves its primary goal.

Protagonist (PTGX) Up on Positive Results From FRONTIER Study

Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Protagonist Therapeutics (PTGX) Soars 51.9%: Is Further Upside Left in the Stock?

JNJ-2113 (formerly PN-235) met the study's primary endpoint, with a statistically significantly higher proportion of adult patients with moderate-to-severe plaque psoriasis achieving PASI-75 in all treatment groups at Week 16 compared to placebo Treatment was well tolerated, with no meaningful difference in frequency of adverse events across treatment groups NEWARK, Calif. , March 7, 2023 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company"), today announced positive topline results from its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), in the FRONTIER 1 Phase 2b clinical trial evaluating the oral Interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in patients with moderate-to-severe plaque psoriasis.

Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis

Protagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last?

NEWARK, Calif. , Dec. 21, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.

Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 323.4% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Protagonist Therapeutics (PTGX) Climb 323% to Reach the Level Wall Street Analysts Expect?

NEWARK, Calif. , Dec. 1, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.

Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit

The mean of analysts' price targets for Protagonist Therapeutics (PTGX) points to a 337.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 337%

Continued execution of Phase 3 VERIFY study of rusfertide in polycythemia vera Arturo Molina, M.D., M.S. named Chief Medical Officer, providing medical, clinical development, and strategic leadership to the rusfertide clinical development program Three rusfertide poster presentations to be shared at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH) in December NEWARK, Calif.

Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update

NEWARK, Calif. , Nov. 3, 2022  /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") announced today that three abstracts related to the Company's rusfertide program have been accepted as poster presentations at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH), taking place December 10-13, 2022 at the Ernest N.

Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting

Accomplished hematologist-oncologist will provide medical, clinical development, and strategic operational leadership to the ongoing rusfertide Phase 3 development program NEWARK, Calif. , Nov. 2, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the appointment of Arturo Molina, M.D.

Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P.

The average of price targets set by Wall Street analysts indicates a potential upside of 322.3% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 322% as Wall Street Analysts Expect?

The consensus price target hints at a 301.5% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 302%

Continued focus on Phase 3 VERIFY study of rusfertide in polycythemia vera (PV) Presented new, positive data from Phase 2 REVIVE study of rusfertide in PV at the 2022 ASCO Annual Meeting and the EHA2022 Congress Strong cash position, with cash runway through end of 2024 NEWARK, Calif. , Aug. 4, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Protagonist has recently faced a number of mishaps. These make the stock risky.

Protagonist: Too Many Red Flags

NEWARK, Calif. , June 1, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.

Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference

Kymera Therapeutics

Kezar Life Sciences Inc

It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. The post 3 Biotech Stocks to Buy Before They Boom appeared first on InvestorPlace.

3 Biotech Stocks to Buy Before They Boom

Enrollment completed and dosing resumed in the ongoing Phase 2 REVIVE study Resumption of rusfertide administration after suspension restored therapeutic benefits including hematocrit control, reduced red blood cell count, and decreased phlebotomy rate NEWARK, Calif., May 26, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) today announced new data from its ongoing Phase 2 REVIVE study evaluating rusfertide in patients with polycythemia vera (PV).

Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022

Bristol-Myers

Eli Lilly

Pfizer

Pfizer Inc.'s PFE, +0.96% promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030 if it's approved by U.S. regulators next year.

A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants?

New York, New York--(Newsfile Corp. - May 17, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) resulting from allegations that Protagonist Therapeutics may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Protagonist Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees...

ROSEN, A TOP RANKED FIRM, Encourages Protagonist Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - PTGX

NEW YORK , May 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ: PTGX). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protagonist Therapeutics, Inc. - PTGX

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 35.82% and 33.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Protagonist Therapeutics Stock (PTGX)